Pediatrics – Infectious Diseases | Page 11 of 19 | Links Medicus Content Curation & Alerts in Medicine

Antibiotics in critically ill children—a narrative review on different aspects of a rational approach.

16 Dec, 2021 | 08:53h | UTC

Antibiotics in critically ill children—a narrative review on different aspects of a rational approach – Pediatric Research

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

15 Dec, 2021 | 08:43h | UTC

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection – Nature Medicine

News release: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford

Commentaries on Twitter

Hugely important work from @JuliaHCox and colleagues:

In people <40, Pfizer carries a much lower risk of myocarditis than either Moderna **or SARS-CoV-2 infection** (annotations added)https://t.co/wqRts3ALqy pic.twitter.com/fnn1T39h1b

— David Juurlink (@DavidJuurlink) December 14, 2021

A case series published in @NatureMedicine shows an increased risk of myocarditis after receiving the Astra-Zeneca-Oxford, Pfizer-BioNTech and the Moderna COVID-19 vaccines, but SARS-CoV-2 infection carried a greater risk of myocarditis. https://t.co/6y7pZlJN70 pic.twitter.com/cBlKz9sUkg

— Nature Portfolio (@NaturePortfolio) December 14, 2021

Just published @NatureMedicine
The most comprehensive assessment of the rare events of myocarditis, pericarditis, arrhythmias after COVID and AZ, mRNA vaccineshttps://t.co/0bEdMJSLXg pic.twitter.com/eC5JOx0CmG

— Eric Topol (@EricTopol) December 14, 2021

Systematic Review: Antibiotics for adults and children with sore throats.

10 Dec, 2021 | 10:02h | UTC

Summary: Antibiotics for adults and children with sore throats – Cochrane Library

Original Research: Antibiotics for treatment of sore throat in children and adults – Cochrane Library

[Preprint] Risk of Hospitalization, severe disease, and mortality due to COVID-19 in children with SARS-CoV-2 infection in Germany – “overall hospitalization rate associated with SARS-CoV-2 infection was 35.9 per 10,000 children, ICU admission rate was 1.7 per 10,000 and case fatality was 0.09 per 10,000”.

8 Dec, 2021 | 10:18h | UTC

Risk of Hospitalization, severe disease, and mortality due to COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany – medRxiv

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

Review: Should children under 12 years of age be vaccinated against COVID-19?

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

7 Dec, 2021 | 10:19h | UTC

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

News Release: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

Review of 4,470 cases of Multisystem Inflammatory Syndrome in Children in the US.

7 Dec, 2021 | 10:08h | UTC

Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021 – Clinical Infectious Diseases

WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

AAP Clinical Report | Tuberculosis Infection in Children and Adolescents.

2 Dec, 2021 | 09:58h | UTC

Tuberculosis Infection in Children and Adolescents: Testing and Treatment – Pediatrics

EMA recommends approval of Pfizer-BioNTech vaccine for children aged 5 to 11.

26 Nov, 2021 | 08:47h | UTC

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 – European Medicines Agency

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

What COVID vaccines for young kids could mean for the pandemic.

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

Commentary on Twitter

‼️ EMA recommends approval of BioNTech/Pfizer’s #COVID19vaccine, Comirnaty, for children aged 5 to 11.

In this population, the dose of #Comirnaty will be lower than that used in people aged 12 and above.

Read the full press release: https://t.co/uqqBAklVvl pic.twitter.com/NZQhli4SDl

— EU Medicines Agency (@EMA_News) November 25, 2021

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

26 Nov, 2021 | 08:35h | UTC

Persistent symptoms following SARS-CoV-2 infection among children and young people: a meta-analysis of controlled and uncontrolled studies – Journal of Infection

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Long COVID: the physical and mental health of children and non-hospitalized young people after SARS-CoV-2 infection – one in seven children may still have symptoms 15 weeks after infection.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Cohort study: Risk factors for long covid in previously hospitalized children.

M-A: More than 50 long-term effects of COVID-19.

WHO Interim statement on COVID-19 vaccination for children and adolescents.

25 Nov, 2021 | 10:49h | UTC

Interim statement on COVID-19 vaccination for children and adolescents – World Health Organization

WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

24 Nov, 2021 | 08:51h | UTC

News Release: WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19 – World Health Organization

Guideline: Living guidance for clinical management of COVID-19 – World Health Organziation

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

Systematic Review: Vaccines for preventing rotavirus diarrhea.

24 Nov, 2021 | 08:20h | UTC

Vaccines for preventing rotavirus diarrhoea: vaccines in use – Cochrane Library

Summary: Are rotavirus vaccines safe and effective in preventing rotavirus diarrhoea in infants and children? – Cochrane Library

Commentary: Vaccines for preventing rotavirus diarrhoea: an updated Cochrane review – Cochrane Library

Review: Prevention of emerging infections in children.

23 Nov, 2021 | 08:17h | UTC

Prevention of Emerging Infections in Children – Pediatric Clinics of North America

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

21 Nov, 2021 | 22:56h | UTC

Single-dose HPV vaccine highly effective, researchers say – University of Washington School of Medicine

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

19 Nov, 2021 | 10:57h | UTC

COVID-19 vaccines for children – Science

Commentary on Twitter

"Although it is true that most children experience asymptomatic or mild COVID disease, some will get quite sick, and a small number will die.

It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis" @DrPaulOffit et al.https://t.co/mvXHXdiYha

— Madhu Pai, MD, PhD (@paimadhu) November 18, 2021

Review: Should children under 12 years of age be vaccinated against COVID-19?

18 Nov, 2021 | 08:56h | UTC

Should children be vaccinated against COVID-19? – Archives of Disease in Childhood

Commentary from the author on Twitter (thread – click for more)

Should #children be vaccinated against #COVID19?

Our review outlines the points to consider in weighing up whether all healthy children under 12y should be vaccinated against COVID-19.https://t.co/JtoOr2TZoq #medpeds #IDTwitter #PaedsID #tweetiatrician #paediatrics

?1/n pic.twitter.com/g4UGu3pMsE

— Nigel Curtis (@nigeltwitt) November 6, 2021

Covid: Children in UK told to delay jab for 12 weeks after infection.

18 Nov, 2021 | 08:54h | UTC

Covid: Children told to delay jab for 12 weeks after infection – BBC

Original Report: Joint Committee on Vaccination and Immunisation (JCVI) advice on COVID-19 vaccination in people aged 16 to 17 years: 15 November 2021

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

12 Nov, 2021 | 10:39h | UTC

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – Nature

[Preprint] Study confirms children’s extremely low risk of death from Covid-19 – “99·995% of children and young people with a positive SARS-CoV-2 test survived”.

Study: Children and young people remain at low risk of COVID-19 mortality

Commentaries on Twitter

Just published @NatureMedicine
An in-depth analysis of the 25 children who died from Covid in England during the 1st year of the pandemichttps://t.co/QK3gk1BXy5
Great that 99.995% of children w/ a positive test survived (not what is driving the need for ?in kids) pic.twitter.com/moXKl8ysmA

— Eric Topol (@EricTopol) November 11, 2021

A clinical review of all pediatric deaths in England from March 2020 to February 2021 attributes 25 deaths to SARS-CoV-2 infection and identifies risk factors to guide interventions, according to a @NatureMedicine article. https://t.co/Bpjhf5sgow pic.twitter.com/v24Zf9CsXK

— Nature Portfolio (@NaturePortfolio) November 11, 2021

WHO, CDC | Global progress against measles threatened amidst COVID-19 pandemic.

12 Nov, 2021 | 10:27h | UTC

News Release: Global progress against measles threatened amidst COVID-19 pandemic – World Health Organization

Report: Progress Toward Regional Measles Elimination — Worldwide, 2000–2020 – CDC Morbidity and Mortality Weekly Report

Commentary: Measles is a renewed global threat after 22 million babies missed their vaccines during the pandemic, CDC warns – CNN

Commentary on Twitter (thread – click for more)

While reported #measles cases have fallen compared to previous years, progress toward measles elimination continues to decline and the risk of outbreaks is mounting, according to a ? report from @CDCgov & WHO.

? https://t.co/EjRVRexcGd pic.twitter.com/KnBU5RZn5i

— World Health Organization (WHO) (@WHO) November 10, 2021

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

11 Nov, 2021 | 08:52h | UTC

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

10 Nov, 2021 | 07:24h | UTC

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age – New England Journal of Medicine

Commentary on Twitter

In this multi-phase trial, two 10-μg doses of the BNT162b2 vaccine administered 21 days apart were safe, immunogenic, and 90.7% effective against #COVID19 in 5-to-11-year-old children. #Covid19vaccine https://t.co/kuj2eI4YCE pic.twitter.com/BWEkYxn8a0

— NEJM (@NEJM) November 9, 2021